Drugs / JANX008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05783622 | Apr 2023 → Jul 2026 overdue | colorectal carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma +3 | Janux Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | Janux Therapeutics | Results Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development januxrx.com ↗
While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs. |
| 2024-02-26 | Janux Therapeutics | Results Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors januxrx.com ↗
A subject with NSCLC achieved a RECIST PR maintained through 18-weeks with 100% target lung lesion reduction and elimination of liver metastasis with no CRS or TRAEs |
| 2022-12-27 | Janux Therapeutics | Regulatory Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors januxrx.com ↗
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that the Company has submitted the investigational new drug (IND) application for JANX008 to the U.S. Food and Drug Administration, an EGFR-TRACTr in development for the treatment of EGFR-expressing solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN). |
| 2022-04-26 | Janux Therapeutics | Results Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr januxrx.com ↗
Enhanced PK profile and high exposure of TRACTrs were well tolerated in NHP safety studies with limited healthy tissue toxicities and cytokine release syndrome |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JANX008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05783622 ↗ |
| Route | Intravenous | “JANX008 is dosed via IV weekly in a 21-day cycle” NCT05783622 ↗ |